Back to Search
Start Over
Tolerogenic dendritic cells as a therapy for treating lupus
- Source :
- CLINICAL IMMUNOLOGY, Artículos CONICYT, CONICYT Chile, instacron:CONICYT
- Publication Year :
- 2013
- Publisher :
- ACADEMIC PRESS, 2013.
-
Abstract
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that is characterized by the over production of auto-antibodies against nuclear components. Thus, SLE patients have increased morbidity and, mortality compared to healthy individuals. Available therapies are not curative and are associated with unwanted adverse effects. During the last few years, important advances in immunology research have provided rheumatologists with new tools for designing novel therapies for treating autoimmunity. However, the complex nature of SLE has played a conflicting role, hindering breakthroughs in therapeutic development. Nonetheless, new advances about SLE pathogenesis could open a fruitful line of research. Dendritic cells (DCs) have been established as essential players in the mechanisms underlying SLE, making them attractive therapeutic targets for fine-tuning the immune system. In this review, we discuss the recent advances made in revealing the mechanisms of SLE pathogenesis, with a focus on the use of DCs as a target for therapy development.
- Subjects :
- Systemic lupus erythematosus
business.industry
medicine.medical_treatment
Immunology
Immunotherapy
Dendritic Cells
medicine.disease
medicine.disease_cause
Immunity, Innate
Immune tolerance
Autoimmunity
Pathogenesis
Immune system
immune system diseases
Healthy individuals
Immune Tolerance
Immunology and Allergy
Medicine
Humans
Lupus Erythematosus, Systemic
skin and connective tissue diseases
business
Adverse effect
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- CLINICAL IMMUNOLOGY, Artículos CONICYT, CONICYT Chile, instacron:CONICYT
- Accession number :
- edsair.doi.dedup.....0bdff77bf7b541a83089a0b2cf1c5593